The Impact Of Single-Use Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Impact Of Single-Use Systems
Jerold Martin, senior vice president global technical affairs, at Pall Life Sciences, explains the importance and impact of single-use systems in sterile environments.


Pharmaceutical Technology Europe
Volume 23, Issue 12

How have single-use systems advanced in recent years and what impact has this had on cleanroom environments?

Single-use systems have only recently been introduced into final-filling cleanroom environments. A key strength is their recognition as “closed systems” by drug manufacturers and regulatory authorities. Many drug and vaccine manufacturers see this as a great opportunity to work in non-classified or lower-classified areas (e.g., Grade C or D/Class 100,000/ISO 8), and some have already applied this approach in new facilities and expansions. A key enabler of single-use systems in final-filling areas has been the innovative development of sterile connectors, which enable sterile connections in nonclassified environments. These sterile connectors are valued as providing higher assurance of containment than traditional aseptic connections that must be performed under Grade A/Class 100/ISO 5 conditions. Although perhaps having minimal impact on existing cleanroom facilities, these advanced capabilities are stimulating designers of new aseptic filling facilities to consider reduction in cleanroom spaces and classifications, greatly reducing the potential cost to put up new aseptic filling suites.

When designing and building a new cleanroom facility, what consideration should be given to single-use systems?

Implementing single-use systems in a new cleanroom facility can enable reduction in the size of the cleanroom by allowing for downgrades at every stage, working in grey areas for most of the process and limiting Class A (Grade 100, ISO 8) areas to around the filling needles. This is further facilitated through the use of complementary technologies within cleanrooms, for example, single-use port approaches on isolators that enable single-use system integration into Grade 100 areas. The primary benefit of these technologies is a reduction in controlled environment class and areas, which can greatly decrease facility build cost and time, as well as labour resources, time and the costs of environmental monitoring, maintenance and other ongoing quality control activities.

How do single-use, closed systems help reduce or, in some cases, eliminate the need for classified cleanroom environments?

Closed systems eliminate the risk of external contamination—including chemical, microbial or particulate. Sterile connectors have been shown to maintain sterile pathways even when externally contaminated with up to one million bacteria per unit and in bacterial aerosols far higher than would occur even in an uncontrolled environment. Because clean sterile fluid pathways are maintained independent of the environment, classified cleanroom conditions are only needed at points of filling. Conservative practices and tradition may preclude complete elimination of controlled spaces, but single-use systems will enable manufacturing in smaller and lower classification areas, greatly reducing facility construction and operating costs. Regulatory acceptance of sterile connection technologies is increasing at the pace of single-use technology implementation, such that in the coming years, both the user base and data for sterile connector technology will only further increase.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here